Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMIJNLG)

Drug Name
Semapimod Drug Info
Synonyms CPSI-2364; Semapimod (oral); Semapimod (oral), Cytokine PharmaSciences
Indication
Disease Entry ICD 11 Status REF
Autoimmune diabetes 5A10 Phase 2 [1]
Inflammatory bowel disease DD72 Phase 2 [1]
Cross-matching ID
PubChem CID
5745214
CAS Number
CAS 352513-83-8
TTD Drug ID
DMIJNLG

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proto-oncogene c-RAF (c-RAF) TTB18GJ RAF1_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Proto-oncogene c-RAF (c-RAF) DTT RAF1 8.016 7.989 7.641 7.915
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Autoimmune diabetes
ICD Disease Classification 5A10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Proto-oncogene c-RAF (c-RAF) DTT RAF1 2.11E-03 0.21 1.51
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00038766) CNI-1493 for Treatment of Moderate to Severe Crohn's Disease. U.S. National Institutes of Health.
2 Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol. 2005 Aug 15;175(4):2293-300.